Abivax (NASDAQ:ABVX) Issues Quarterly Earnings Results

Abivax (NASDAQ:ABVX) announced its quarterly earnings results on Monday. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.24) by $1.00, reports. The business had revenue of $1.45 million for the quarter, compared to analyst estimates of $1.80 million.

Abivax Stock Performance

NASDAQ ABVX opened at $110.17 on Wednesday. The firm has a 50-day moving average price of $119.11 and a two-hundred day moving average price of $110.93. Abivax has a 12-month low of $4.77 and a 12-month high of $148.83. The company has a market capitalization of $8.72 billion, a P/E ratio of -20.52 and a beta of 1.00. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03.

Institutional Investors Weigh In On Abivax

Several institutional investors have recently made changes to their positions in the stock. TCG Crossover Management LLC grew its position in Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after buying an additional 1,055,000 shares in the last quarter. UBS Group AG raised its holdings in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after acquiring an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. raised its holdings in Abivax by 0.4% in the 4th quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock valued at $439,714,000 after acquiring an additional 14,000 shares in the last quarter. Morgan Stanley lifted its position in shares of Abivax by 114.3% during the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after acquiring an additional 1,681,277 shares during the period. Finally, Vestal Point Capital LP grew its holdings in shares of Abivax by 90.0% during the 4th quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock worth $256,224,000 after purchasing an additional 900,000 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ABVX has been the topic of several research analyst reports. Citigroup reissued a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Barclays lifted their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday. Guggenheim reiterated a “buy” rating and issued a $175.00 price target on shares of Abivax in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group started coverage on Abivax in a report on Monday, March 16th. They set a “buy” rating and a $160.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $137.15.

Key Headlines Impacting Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Barclays raised its price target to $148 and kept an “overweight” rating, highlighting analyst confidence in upside from upcoming catalysts. Barclays raises price target
• Positive Sentiment: Abivax reported quarterly results that materially beat EPS expectations (reported loss per share smaller than forecast), which reduces near-term execution risk relative to estimates. Revenue modestly missed. Quarterly results press release
• Neutral Sentiment: Abivax announced appointments of three key executives — a governance/operational update that may help execution but is not an immediate revenue catalyst. Abivax appoints three key executives
• Neutral Sentiment: Company filed full-year 2025 results and business updates; investors should review the release for detail on cash position, pipeline timing and guidance. Full-year 2025 results and updates
• Neutral Sentiment: Multiple short-interest reports show a large increase but the published figures read as 0 shares / NaN changes and a 0.0 days-to-cover — the data appears unreliable, so don’t read meaningful short-squeeze signals from these filings.
• Negative Sentiment: Management publicly downplayed urgency for M&A, saying the company prefers to wait for a key trial data readout in Q2 and is preparing for a capital raise; that reduces takeover speculation and raises dilution/funding concerns in the near term. CNBC: Abivax in no rush for a deal Benzinga: CEO downplays sale talk

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.